Chemical Science · 2024 · 10 citations · 37 references
PharmacyMedicinal ChemistryPharmacologyDrug DiscoveryStructural BiologyVirologyLigand BindingLigand-mediated TargetingProtein-ligand BindingReceptor-ligand InteractionsTargeting LigandsViral TropismAffinity SelectionAntiviral RecognitionLectin Binding SpecificityLectin InteractionsReceptor Binding SpecificityReceptorsSelectivityStructural Basis Of Receptor Recognition
of 12.7μM ± 1 μM (ITC) and is the first known L-SIGN selective ligand, showing 50-fold selectivity over DC-SIGN (SPR). The X-ray structure of the L-SIGN CRD/Man84 complex reveals the guanidinium group's role in achieving steric and electrostatic complementarity with L-SIGN. This allows us to trace the source of selectivity to a single amino acid difference between the two CRDs. NMR analysis confirms the binding mode in solution, highlighting Man84's conformational selection upon complex formation. Dimeric versions of Man84 achieve additional selectivity and avidity in the low nanomolar range. These compounds selectively inhibit L-SIGN dependent trans-infection by SARS-CoV-2 and Ebola virus. Man84 and its dimeric constructs display the best affinity and avidity reported to date for low-valency glycomimetics targeting CLRs. They are promising tools for competing with SARS-CoV-2 anchoring in the respiratory tract and have potential for other medical applications.
37
Lectins enhance SARS-CoV-2 infection and influence neutralizing antibodies
Florian A. Lempp, Leah Soriaga, Martin Montiel-Ruiz et al. · Nature · 2021 · 326 citations · Full text